MDT

ACCE-researched
Medtronic plc. Ordinary Shares
Healthcare · Medical Devices · NYSE · United States
$92.13-0.69%
Market cap $117.8BNext earnings 2026-09-01Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$92.13+0.0%
confidence-weighted across 5 of 6 models
Now $92.13
$92.13
$41.69$140.89
TrimSilver64
Price vs fair value
31.8% above
-24.1% to fair value
ACCE score
66
out of 100
Analysts
53% buy
32 covering
P/E
22.7x
forward 14.4x
1-year return
-3.6%
Dividend yield
3.13%
Unlock the ACCE read
INVESTOR

Overview

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

-2.6% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Mixed53% buy · 32 covering analysts
● Strong buy 12● Buy 5● Hold 13● Sell 1● Strong sell 1
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 17.5x22.7xhigh 52.5x
ROEbetter than 33% of peers
low 9%11%high 38%
Div yieldbetter than 100% of peers
low 0.0%3.1%high 3.1%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
SYKStryker Corporation Common Stock$105.5B28.516.5%0.711.3%-Compare
ABTAbbott Laboratories Common Stock$177.6B33.210.6%0.252.5%-Compare
BSXBoston Scientific Corporation Common Stock$62.8B17.515.3%0.470.0%-Compare
EWEdwards Lifesciences Corporation Common Stock$50.9B52.59.2%0.060.0%-Compare
SHL.DESiemens Healthineers$48.4B19.212.2%0.612.6%-Compare
DXCMDexCom Inc. Common Stock$33.7B35.338.5%0.460.0%-Compare

Sector report card

Where MDT ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+1.3%
1 month
-2.1%
3 months
+16.1%
6 months
+6.9%
YTD
-4.1%
1 year
-3.6%

SEC filings

40 filings
September 2026
Sep 17
8-KCurrent reportPeriod 2026-09-17
Sep 17
Form 4Insider transactionPeriod 2026-09-16
Sep 16
Form 4Insider transactionPeriod 2026-09-15
37 more filings + AI summaries on Investor+.INVESTOR